{
  "docId": "019de070-8dac-72dd-8b30-47dcdd26ea78",
  "docSlug": "14b2a339e11f22ed5b817a794c035302",
  "documentTitle": "Chimerix | Mergers and Acquisitions Presentation Deck | 26 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 26,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 45,
  "notes": "The table displays Treatment-Emergent Adverse Events (TEAEs) for 30 patients.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-8dac-72dd-8b30-47dcdd26ea78/12",
  "deckHref": "/decks/019de070-8dac-72dd-8b30-47dcdd26ea78",
  "deckJsonHref": "/decks/019de070-8dac-72dd-8b30-47dcdd26ea78.json",
  "deckAnchorHref": "/decks/019de070-8dac-72dd-8b30-47dcdd26ea78#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Integrated safety database for NDA will consist of >350 glioma patients; No discontinuations due to drug-related adverse events (AEs); Single weekly dosing until progression; Safety profile and oral dosing enable: Fixed dosing in adults, High rate of compliance, Multiple therapeutic settings, Combination therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5513a843-f9c1-424f-9147-06edc625de1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.45,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "All AEs reported in >10% of pts with at least one event attributed by investigator as a least possibly-related to study drug",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29c657dd-1c31-45db-845b-7576af92c31f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.68,
        "w": 0.51,
        "x": 0.464,
        "y": 0.17
      },
      "kind": "table",
      "text": "AEs in Recurrent H3 K27M-mutant Glioma Patients (N=30) table showing All TEAE, Gr3-4 TEAE, and ONC201-Related All TEAE percentages for various medical conditions.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "667eda13-2481-4a5f-a84f-31967e4e1515",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ONC201 demonstrates attractive safety profile, oral administration",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de8f4c74-8dec-47c8-8060-b9a59657da2f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}